A new analysis from Monash University suggests that low-dose aspirin may be linked to a dramatically lower risk of dementia in older adults with certain genetic characteristics. Researchers found that people with a specific genetic profile who took aspirin had a 70 percent lower relative risk of developing dementia, raising the possibility that genetic testing could eventually help identify people who might benefit from preventive treatments.

The findings, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, were based on genetic data from more than 13,500 participants in the landmark ASPREE Trial (Aspirin in Reducing Events in the Elderly). Scientists examined whether differences in participants’ genes could help explain why aspirin might affect dementia risk differently from one person to another.